ICYMI: Join global experts in a replay of #EuroPCR 2024 case-based discussion of complex cases performed with #DynamX® Coronary #Bioadaptor System and how restoring vessel viability leads to unique clinical benefits. Watch the recording and learn more: https://lnkd.in/eCP6iaHS Thank you Drs. Flavio Ribichini, Johan Bennett, Mirvat Alasnag, Michał Hawranek, Anthony Wong and Ganapathi Palaniappan for an insightful discussion! DynamX Coronary Bioadaptor System is CE marked. Not approved in the U.S. #Medtech #Innovation #Cardiology #Cardiovascular #leavetherightthingbehind PMN 1940 REV A
Elixir Medical Corporation
Medical Device
Milpitas, CA 5,884 followers
Elixir Medical is committed to transforming care for patients with heart and vascular disease through innovation.
About us
Elixir Medical is committed to transforming care of patients with heart and vascular disease through innovation. Since 2005, the company has continually sought to improve the treatment of vascular disease with: - Drug-eluting coronary stent systems (DES) - Fully resorbable drug-eluting scaffold systems (BRS) - Drug-eluting coronary bioadaptor systems Its latest innovation — the DynamX™ Coronary Bioadaptor System — is designed to be a significant advancement beyond drug-eluting stents (DES). Elixir Medical’s innovations are designed to make a meaningful change in patients’ lives. The company does not simply want to engineer a better medical device. Saving lives and helping patients enjoy their daily life is what drives us every day.
- Website
-
http://www.elixirmedical.com
External link for Elixir Medical Corporation
- Industry
- Medical Device
- Company size
- 51-200 employees
- Headquarters
- Milpitas, CA
- Type
- Privately Held
- Founded
- 2005
- Specialties
- Cardiac and Vascular Interventional Medical Devices
Locations
-
Primary
920 N. McCarthy Blvd.
Suite 100
Milpitas, CA 95035, US
-
IDA Business and Technology Park
Carrick-on-Shannon, Co. Leitrim, IE
Employees at Elixir Medical Corporation
Updates
-
We are thrilled that the #DynamX bioadaptor animation, developed in collaboration with Kadiko, was recently honored in the 2024 Telly Awards. 🥇 Gold Winner in the Pharmaceuticals – Non-Broadcast Category 🥈 Silver Winner in the Craft-3D Animation Category The combo of human anatomy visuals and detailed method of action creates a realistic portrayal of the #bioadaptor enabling vessel pulsatility in action. Watch the award-winning animation here: https://lnkd.in/emHYRQqE #Bioadaptor #Medtech #Innovation #Cardiology CE marked. Not for sale in the U.S. PMN 1890 REV A
We are proud to announce that Kadiko, formerly named Viewstream, has been awarded sixteen (16) awards from the 45th Annual Telly Awards. Kadiko has been awarded one (1) Gold Award, eight (8) Silver Awards, and seven (7) Bronze Awards in areas such as 3D Animation, Art Direction, Motion Graphics and Design, and Directing. We're so grateful to work with clients like Elixir Medical Corporation, ENGIE North America Inc., UPS and IGNYTE AI, who believe in the power of amazing creative!
-
📣 Our #DynamX Sirolimus-Eluting Coronary #Bioadaptor System has been granted Breakthrough Device Designation by the FDA for the treatment of symptomatic ischemic heart disease. Learn more here: https://lnkd.in/ehVvSY5R #Medtech #Innovation #Cardiology CE marked. Not for sale in the U.S. PMN 1892 REV A
-
DynamX shows excellent performance with “the rate of target lesion failure essentially unchanged over time.” - TCTMD “The study suggests “an edge” with Bioadaptor in terms of TLF over the drug-eluting stent.” - Professor Robert Byrne. Read more about the #BIOADAPTOR RCT two-year data presented at #EuroPCR in a recent article from Michael O'Riordan in TCTMD: https://lnkd.in/e5EiHPU4 Dr. Stefan Verheye Dr. Mirvat Alasnag #Bioadaptor #Medtech #Innovation #Cardiology CE marked. Not approved in the U.S. PMN 1887 REV A
-
ICYMI: At #EuroPCR 2024, we presented late-breaking clinical results from the DESyne® BDS Plus Randomized Controlled Trial (RCT) that demonstrated the safety and efficacy of the innovative site specific anti-thrombotic drug therapy (TRx) platform. The 12-month results demonstrated: • Significant 77% lower TLF rate of 2.1% for DESyne BDS Plus compared to 9.3% for contemporary DES (p=0.03). • No definite or probable stent thrombosis, cardiovascular death, or target vessel myocardial infarction (TV-MI), were observed in DESyne BDS Plus treated patients Learn more about the results: https://lnkd.in/eNVFUD2U DESyne BDS Plus is for investigational use only. Not approved in the U.S. #BDSPlus #Cardiovascular #Medtech #Innovation
-
ICYMI: New PINNACLE I study data presented at #EuroPCR 2024 demonstrate effectiveness of the LithiX™ Hertz Contact Intravascular Lithotripsy System’s unique mechanism of action across a broad range of moderate to severe calcified lesion morphologies with more than 90% of lesions demonstrating fractures, overall very deep fracture depth (average depth > 0.80mm) and optimal stent expansion with excellent lumen gain. Learn more about the results: https://lnkd.in/enu8PvkK Hertz Contact Intravascular Lithotripsy is for investigational use only. Not approved in the U.S. #Lithotripsy #Cardiovascular #Medtech #Innovation
-
ICYMI: At #EuroPCR 2024, we shared late-breaking two-year data showing significant clinical advantages of the #DynamX® Coronary Bioadaptor System over 3rd generation standard of care drug-eluting stent (DES): • Continuing separation of target lesion failure (TLF) KM curves, with flattening of the DynamX curve and as expected linear increase for DES • Significant 65% reduction in TLF rate (1.9% vs. 5.5%; p=0.046) • Significant 68% reduction in target vessel failure (TVF) rate (1.9% versus 6.0%; p=0.029) • Significant 78% reduction in TLF rate in left anterior descending (LAD) artery lesions (1.9% vs. 8.7%; p=0.028) Learn more about the BIOADAPTOR Randomized Controlled Trial (RCT) results: https://lnkd.in/eTwz3A87 CE marked. Not for sale in the U.S. #Bioadaptor #Medtech #Innovation #Cardiology
-
Dr. Mirvat Alasnag on the 5 trials that will impact her practice presented at #EuroPCR. Check out her thoughts on our DESyne #BDSPlus and PINNACLE I data: #Medtech #Innovation #cardiovascular PMN 1861 Rev A
We were joined by Dr Mirvat Alasnag at #EuroPCR who shared her ‘5 Trials That Will Change My Practice’ Trials covered in detail include: - IRONMAN II - DESyne BDS Plus - NOTION II - LANDMARK - PINNACLE
EuroPCR 2024: 5 Trials That Will Change My Practice With Dr Mirvat Alasnag
https://www.youtube.com/
-
We’re thrilled that #EuroPCR recognized the two-year BIOADAPTOR RCT results as one of the top three trial updates and DESyne® BDS Plus as a top innovation in the 2024 Highlights presentation! 🎖🏆 Learn more about the data: https://lnkd.in/eDPXjDZ5 #Bioadaptor #Medtech #Innovation #Cardiology #BDSPlus #Cardiovascular
-
Congratulations to Dr. Anthony Siu-Fung Wong and the interventional cardiology team from United Christian Hospital, Hong Kong, for selection of their DynamX case as a finalist for the DynamX Xcase Competition 2024! The interventional cardiology team, led by Dr. Tak-Shun Chung, tackled the critical situation of acute left main MI alongside the technical challenge of preserving trifurcation LM anatomy using inverted Culotte LM bifurcation stenting with double bioadaptors. This innovative approach illustrated the culotte technique with mismatched sizes of 2 branches while highlighting the merit of bioadaptors in adapting to dynamic vessel size in AMI settings. The case resulted in good final angiographic results with TIMI 3 flow to all major vessels and branches. Congratulations, Dr. Wong and the United Christian Hospital team, on this remarkable achievement! #XCaseCompetition #DynamX #bioadaptor PMN 1854 Rev A